MedTrace Logo

Evaluation of an Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting

NCT01610063 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 227

Last updated 2017-03-30

Study results available
· View outcomes & findings →

Summary

This was a study of a genotyping tool that reported on how subjects responded to medications and could be used in a community psychiatry practice to improve medication choice for depression. After the DNA test, an interpretive report was provided to the subjects' physicians. The hypothesis of this pilot study was that it was feasible to use this pharmacogenomic algorithm in a new setting to treat depressed subjects..

Conditions

Interventions

OTHER

Pharmacogenomic algorithm

Genetic test results for 4 genes were put through algorithm and provided to physician for guidance prescribing medication.

Sponsors & Collaborators

  • Assurex Health Home

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Daniel K. Hall-Flavin · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-11-30
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01610063 on ClinicalTrials.gov